

2M2026 BUSINESS UPDATES

IMEXPHARM CORPORATION



EXPLANATORY NOTE

Due to the impact of the Tet holiday, which fell in different months this year and last year, a standalone year-over-year comparison of January and February would not provide meaningful insights. Therefore, we are reporting our cumulative results for the first two months of the year (2M) to ensure a more accurate and relevant performance analysis.



Robust profitability growth amidst topline volatility

2M NET REVENUE

371 bn

▼ 2% YoY

2M EBITDA

91 bn

▲ 17% YoY

2M PBT

70 bn

▲ 24% YoY

ETC

▼ 8% YoY (*)

OTC

▼ 1% YoY (*)

- New tender win rates were pressured by intensified competition following the entry of new EU-GMP certified manufacturing facilities. In response, we adopted a more defensive posture to prioritize margin protection. We are accelerating ETC performance through a robust marketing rollout of new product launches, prioritizing high-margin and new generation antibiotics.
- OTC revenue remained stable as retail pharmacies adopted more conservative inventory strategies in response to rising interest rates. We anticipate a recovery in momentum over the coming months, supported by robust underlying market demand.
- Profitability saw significant year-over-year expansion, propelled by a double-digit reduction in COGS through enhanced operational efficiencies.

(*) Gross revenue before sales deduction

Driving toward double-digit growth through Resilience and Solidarity

The Board of Management and over 900 employees of Imexpharm gathered in Dong Thap on February 13, 2026, for the 2026 Production & Business Plan Conference. This event marked a pivotal moment of solidarity, with the entire organization primed to break new ground and achieve its strategic objectives for the year ahead.



We remain committed to delivering sustainable value to the community


On January 31, 2026, Imexpharm collaborated with the Dong Thap Department of Health to participate in the **'2026 Spring at the Border'** program, providing medical check-ups, medicine, and gifts to meritorious families, students, and underprivileged residents.



On February 8, 2026, Imexpharm organized the **'2026 Lunar New Year Visit and Gift-giving'** program at the Dong Thap Social Support Center.



Resilient stock performance



	IMP	DHG	TRA	DHT	DBD	DMC
YTD avg. daily trading volume	44,807	16,748	10,416	14,960	192,252	875
YTD stock performance	▲ 3%	▲ 2%	▼ (7%)	▼ (0%)	▲ 11%	▲ 2%
Daily trading volume in 2M2026 vs. 2M2025	▲ 25%	▼ (3%)	▲ 371%	▼ (89%)	▲ 81%	▼ (46%)
Market cap (VND billion)	8,316	13,676	2,902	6,331	5,133	2,118

Data as of 27 Feb 2026

Disclaimer

The contents of the IR Newsletter are intended to provide information to institutional investors as well as individual investors of Imexpharm Corporation (Hose: IMP). IMP strives to ensure transparency, completeness, and accuracy of the information in this newsletter.

IMP is exempt from any liability for any losses and damages relating to the use of this document as well as other inaccurate, incomplete, or untimely information about IMP. IMP has the right to change and update information in our newsletters at any time without prior notice.



Contact Us

Imexpharm Investor Relations Team

Office: Floor 24, Flemington Tower, 182 Le Dai Hanh Street, Phu Tho Ward, HCMC

Email: ir@imexpharm.com

Thank You

For further discussion, please contact our IR team
ir@imexpharm.com